Cambridge Healthtech Institute’s 20th Annual

Engineering Antibodies
( 抗体工程 )

New Science and Technologies for the Selection, Engineering and Targeting of Next Generation Therapeutic Antibodies and Biotherapeutics



The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now progressing through development and into the market, great advances in protein science and discovery technology and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. The PEGS Engineering Antibodies conference explores case examples of the most significant emerging technologies used by protein engineers working at the discovery and design stages to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions.

Coverage will include, but is not limited to:


Emerging Technologies in Antibody Discovery

  • CRISPR-Cas9 to engineer hybridoma cell lines for site specific conjugation
  • Innovative molecular and product formats
  • Trends in moving from screening to computational discovery

Antibody Repertoires

  • Emerging applications for deep sequencing and B-cell cloning in antibody discovery
  • Integrating and automating platform technologies for single cell analysis
  • Repertoire sequencing as the basis for biomarkers and patient stratification

Artificial Intelligence and Machine Learning in Antibody Discovery

  • The fundamentals of AI in a discovery organization; tools to sense, reason, act and adapt
  • Data mining and machine learning for retrospective analysis of historical discovery/clinical data
  • Implementing AI in a discovery/development operation: database structures, modeling and pattern recognition platforms, integration with external data sources 

Fast and Nimble Antibody Discovery and Development

  • The DARPA Pandemic Prevention Platform (P3)
  • Case studies of high throughput antibody discovery in small biotechs
  • Best practices for using internal and external resources to accelerate development steps

Improving Specificity

  • Protein engineering considerations for novel routes of administration
  • Tissue-targeted delivery; discovery of tissue markers, depot-based delivery
  • Intracellular delivery and cell penetration

The in vivo Behavior of Antibodies

  • In vivo impacts on binding, PK/PD, post-translational modifications, mode of antibody inhibition
  • Strategies for half-life extension
  • Target-mediated clearance


* 活动内容有可能不事先告知作更动及调整。

Choose your language